Attention around ibogaine safety focuses on the treatment itself, on the cardiac monitoring and the hours under observation. There is a case that the more dangerous period comes afterwards, and it rests on evidence considerably stronger than anything in the ibogaine literature.

The reasoning is straightforward and the arithmetic is unforgiving. Opioid tolerance is what allows a person to survive doses that would kill someone without it. Any intervention that interrupts opioid use reduces tolerance. If use then resumes at the previous amount, the dose that was survivable before may not be. This applies to ibogaine exactly as it applies to any other route to abstinence, and it is the risk least often discussed in material about it.

The central risk

Stated plainly: the period after a successful detoxification carries a raised risk of fatal overdose, and the people at greatest risk are those for whom the detoxification worked best. That is counterintuitive enough that it deserves the underlying data rather than assertion.

It is worth being clear why this gets so little attention in material about ibogaine. The treatment is an event with a clear beginning and end, delivered by someone identifiable, in a setting that can be described. The weeks afterwards are diffuse, happen somewhere else, and belong to nobody in particular. The risk has not moved because the attention has, and a person planning treatment is generally planning the part that is easy to picture.

What the tolerance evidence shows

The clearest demonstration comes from a London cohort of 137 consecutive opiate-dependent adults entering a 28-day inpatient detoxification programme, followed for about a year. Participants were grouped by their tolerance status at discharge: 43 who did not complete detox and remained tolerant, 57 who completed detox but left the programme early with reduced tolerance, and 37 who completed both with lost tolerance [1].

Five people died within 12 months. Three died of overdose within four months, and all three were in the lost-tolerance group. There were no deaths at all among those who did not complete detox, a difference reaching statistical significance [1].

The authors describe the clustering as counterintuitive and illogical unless it derives from loss of tolerance, and state that the finding urgently requires replication [1]. It is a small study resting on three overdose deaths, which is a genuine limitation. It is also consistent with the much larger body of evidence below, which is why it has endured.

Those who died shared other features: they had stayed longer in the programme, been on higher methadone doses, and were more likely to live alone [1]. Living alone is the detail with the most immediate practical meaning, since an overdose witnessed by someone able to call for help or administer naloxone is survivable in a way an unwitnessed one is not.

The mortality data on stopping treatment

The larger evidence comes from a systematic review and meta-analysis covering 15 randomised trials with 3,852 participants and 36 cohort studies with 749,634 participants, examining mortality during and outside opioid agonist treatment [2].

During treatment, all-cause mortality was about half the rate outside it, and the finding held consistently across sex, age, location and other characteristics. Lower rates were observed for suicide, drug-related, alcohol-related and cardiovascular deaths. In the four weeks after treatment ceased, all-cause mortality was about six times higher than during the remainder of time in treatment, and remained roughly double for the rest of the time out of treatment [2].

A sixfold rise in the first four weeks after stopping is the figure that bears directly on this question. Ibogaine treatment, by design, ends opioid use, which places a person in the position those four-week statistics describe. The study's authors note the evidence base is unrefined and most cohorts carried moderate risk of bias, so the precise multiplier should not be treated as exact. The direction and rough magnitude are well supported.

If something here speaks to your situation, the next step is a five-minute provider match profile. We read it personally, take your case to vetted providers, and come back with the ones who say yes — or tell you honestly if ibogaine is not the answer.

Find a provider

One nuance in that meta-analysis cuts the other way and belongs in an honest account. The first four weeks of methadone treatment also carried roughly double the mortality of the rest of time in treatment [2], so beginning agonist treatment is not risk-free either. The pattern across the whole dataset is that transitions are the dangerous points: starting, and above all stopping. A single-dose intervention that ends opioid use is, in those terms, a transition compressed into a few days.

What the guidelines say

This is not a fringe concern. A 2026 evidence-based consensus guideline from the British Association for Psychopharmacology states, in its relapse prevention section, that as with all pharmacological treatment of opioid dependence there are concerns about loss of tolerance to opioids during treatment and the impact on overdose risk [3].

The phrase worth noting is all pharmacological treatment. The guideline is not singling out any particular approach; it is identifying a property shared by every intervention that reduces opioid exposure. Ibogaine is inside that category, and nothing about its mechanism exempts it.

What the ibogaine cohorts reported

The ibogaine follow-up data is thin but not silent on this. The New Zealand observational study followed 14 adults over 12 months, with 11 remaining at the final point and 8 completing every interview. At 12 months, self-reported opioid use in the previous 30 days stood at 45 percent, while urine screens were negative for opioids in 6 of the 8 people tested [4].

Those two figures together describe a realistic picture: a composite drug-use score that fell significantly over the year, alongside a substantial proportion of people who had used opioids at some point in the preceding month. Reduction in use rather than uniform abstinence is what the data show, and the periods of non-use are exactly when tolerance falls.

A Brazilian retrospective analysis of 75 clinic records, where ibogaine was combined with psychotherapy under physician supervision, reported 61 percent abstinent at the time of data collection, with median self-reported abstinence of 5.5 months after a single treatment and 8.4 months after multiple treatments [5]. Read for relapse rather than for success, the same numbers say that a substantial minority were not abstinent and that the median person did eventually resume use.

A retrospective survey of 88 people treated at a residential clinic in Mexico reported that most had their withdrawal eliminated or sharply reduced [6]. That study depended on an anonymous online survey reaching a fraction of former patients, with two authors on the clinic's staff, so it carries obvious limitations as a source on longer-term outcomes.

Across the literature a 2026 review found that most positive efficacy data come from uncontrolled, open-label or retrospective studies at high risk of bias [8]. None of these studies was designed to measure post-treatment mortality, which means the ibogaine-specific evidence on this exact question does not exist.

There is also a selection effect to keep in view when reading these follow-up figures. People who travel abroad and pay for ibogaine treatment are, as a group, more motivated and better resourced than the general population of people with opioid dependence, and the studies above mostly recruited from among those who had already done so. Outcomes in such a group would be expected to look better than outcomes in an unselected population, independent of what the drug did.

Why fentanyl narrows the margin

The general tolerance problem becomes sharper with fentanyl. Its potency by weight is far higher than heroin's, and the illicit supply varies in concentration, so the relationship between a quantity used and a dose received is unpredictable. A person with reduced tolerance encountering an unpredictable supply has very little room for error.

This also compounds an evidence gap. A 2026 review notes that ibogaine's evidence base for opioid use disorder largely predates the fentanyl era [7], so the follow-up data above describes outcomes in populations using heroin and methadone rather than fentanyl.

What appears to reduce the risk

Several measures follow from the evidence, and they concern the weeks after treatment rather than the treatment itself. Not being alone is the one with the clearest support, given that those who died in the London cohort were more likely to live alone [1]. Having naloxone available, and someone present who knows how to use it, converts a potential death into a survivable event.

Knowing that tolerance is gone is itself protective, because the specific danger is returning to a previously familiar amount. The risk arises from a dose that was routine before becoming dangerous, and that only operates on someone who does not realise it.

Structured aftercare is the other element with support in the ibogaine literature specifically, where the Brazilian cohort combined ibogaine with psychotherapy and reported longer abstinence with repeat treatment [5]. That study cannot separate the contribution of the psychotherapy from the ibogaine, which is a limitation, and either way the aftercare was part of what was delivered.

Anyone considering ibogaine as a route out of agonist treatment should also weigh that the mortality evidence for remaining in agonist treatment is the strongest in the field [2]. That comparison belongs in the decision whatever conclusion someone reaches.

Two further points about timing follow from the New Zealand data. Benefits in that cohort emerged over months rather than immediately, with the drug-use composite falling across the 12-month period [4], which implies that the vulnerable window is not brief. And the Brazilian finding of longer abstinence after repeat treatment [5] describes people who had already relapsed once, since a repeat treatment is what follows a return to use. Read that way, relapse appears in the data as a common event in the course rather than an exception to it.

The honest framing

The uncomfortable summary is that the outcome ibogaine treatment aims at, an end to opioid use, is also the condition that makes a subsequent return to use more dangerous. That is not an argument against treatment, and it is not specific to ibogaine. It is a reason the period after treatment deserves at least the planning that the treatment itself receives.

A provider whose arrangements end when a person is discharged has addressed the part of the risk that is easiest to see. The sixfold figure applies to the four weeks that follow [2], and nobody is monitoring during them.

Frequently asked questions

Is the risk higher after ibogaine than during it?

The post-treatment period is where the stronger mortality evidence sits. All-cause mortality was about six times higher in the four weeks after opioid agonist treatment ceased than during the remainder of treatment [2], and overdose deaths after inpatient detox clustered among those who completed it [1].

Why would completing detox increase risk?

Because tolerance falls. The authors of the London cohort describe the clustering of overdose deaths in the lost-tolerance group as inexplicable other than through loss of tolerance, and called for replication [1].

Is this specific to ibogaine?

No. A 2026 consensus guideline identifies loss of tolerance and overdose risk as a concern with all pharmacological treatment of opioid dependence [3].

What do the ibogaine follow-up studies show?

Reduction rather than uniform abstinence. At 12 months in the New Zealand cohort, 45 percent reported opioid use in the previous 30 days while urine screens were negative in 6 of 8 tested [4], and a Brazilian cohort reported 61 percent abstinent with median abstinence of 5.5 months after one treatment [5].

Safety. Ibogaine prolongs the heart's QT interval and can trigger dangerous arrhythmias. Treatment requires an EKG and bloodwork before dosing, continuous cardiac monitoring during, and medically trained staff present. Ibogaine is not safe to take unsupervised.
Disclaimer: This entry is general information, not medical advice.

References

  1. Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, Gossop M. 2003, BMJ 326(7396):959-960. doi:10.1136/bmj.326.7396.959. PMID 12727768. PMC153851. pmc.ncbi.nlm.nih.gov/articles/PMC153851/
  2. Santo T Jr, Clark B, Hickman M, et al. 2021, JAMA Psychiatry 78(9):979-993. doi:10.1001/jamapsychiatry.2021.0976. PMID 34076676. PMC8173472. pmc.ncbi.nlm.nih.gov/articles/PMC8173472/
  3. Sinclair JMA, Kalk NJ, Kaar SJ, et al. 2026, J Psychopharmacol 40(2):227-272. doi:10.1177/02698811251399593. PMID 41731947. PMC13222391. europepmc.org/article/PMC/PMC13222391
  4. Noller GE, Frampton CM, Yazar-Klosinski B. 2018, Am J Drug Alcohol Abuse 44(1):37-46. doi.org/10.1080/00952990.2017.1310218
  5. Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. 2014, J Psychopharmacol 28(11):993-1000. doi:10.1177/0269881114552713. PMID 25271214. europepmc.org/article/MED/25271214
  6. Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. 2017, J Psychedelic Stud 1(2):65-73. doi:10.1556/2054.01.2017.009. PMID 30272050. PMC6157925. europepmc.org/article/PMC/PMC6157925
  7. Shen MR, Owusu-Boaitey K, Murphy ZD, et al. 2026, Front Psychiatry 17:1909149. doi:10.3389/fpsyt.2026.1909149. PMID 42755825. PMC13581858. frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1909149/full
  8. Kervadec E, Bezo A, Serreau R, et al. 2026, J Clin Psychopharmacol. doi:10.1097/jcp.0000000000002197. PMID 42228481. doi.org/10.1097/jcp.0000000000002197